The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase - PubMed (original) (raw)
The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase
D R Alessi. FEBS Lett. 1997.
Free article
Abstract
The protein kinase C (PKC) inhibitors Ro 318220 and GF 109203X have been used in over 350 published studies to investigate the physiological roles of PKC. Here we demonstrate that these inhibitors are not selective for PKC isoforms as was previously assumed. Ro 318220 inhibited MAPKAP kinase-1beta (also known as Rsk-2) in vitro (IC50 3nM) more potently than it inhibited mixed PKC isoforms (IC50 5 nM), and it also inhibited p70 S6 kinase (IC50 15 nM). GF 109203X also potently inhibited MAPKAP kinase-1beta (IC50 50 nM) and p70 S6 kinase (IC50 100 nM) with similar potency to PKC isoforms (IC50 30 nM). The inhibition of MAPKAP kinase-1beta, p70 S6 kinase, and probably other protein kinases, may explain many of the effects previously attributed to PKC.
Similar articles
- Effects of bisindolylmaleimide PKC inhibitors on p90RSK activity in vitro and in adult ventricular myocytes.
Roberts NA, Haworth RS, Avkiran M. Roberts NA, et al. Br J Pharmacol. 2005 Jun;145(4):477-89. doi: 10.1038/sj.bjp.0706210. Br J Pharmacol. 2005. PMID: 15821757 Free PMC article. - Temporal activation of p70 S6 kinase and Akt1 by insulin: PI 3-kinase-dependent and -independent mechanisms.
Somwar R, Sumitani S, Taha C, Sweeney G, Klip A. Somwar R, et al. Am J Physiol. 1998 Oct;275(4):E618-25. doi: 10.1152/ajpendo.1998.275.4.E618. Am J Physiol. 1998. PMID: 9755080 - The design and biological properties of potent and selective inhibitors of protein kinase C.
Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, Kumar H, Lawton G, Lewis EJ, Mulqueen M, et al. Nixon JS, et al. Biochem Soc Trans. 1992 May;20(2):419-25. doi: 10.1042/bst0200419. Biochem Soc Trans. 1992. PMID: 1397642 Review. No abstract available. - Protein kinase C inhibitors as novel anticancer drugs.
Goekjian PG, Jirousek MR. Goekjian PG, et al. Expert Opin Investig Drugs. 2001 Dec;10(12):2117-40. doi: 10.1517/13543784.10.12.2117. Expert Opin Investig Drugs. 2001. PMID: 11772309 Review.
Cited by
- Multisite dephosphorylation and desensitization of conventional protein kinase C isotypes.
Hansra G, Garcia-Paramio P, Prevostel C, Whelan RD, Bornancin F, Parker PJ. Hansra G, et al. Biochem J. 1999 Sep 1;342 ( Pt 2)(Pt 2):337-44. Biochem J. 1999. PMID: 10455020 Free PMC article. - Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.
Mayati A, Bruyere A, Moreau A, Jouan E, Denizot C, Parmentier Y, Fardel O. Mayati A, et al. PLoS One. 2015 Dec 10;10(12):e0144667. doi: 10.1371/journal.pone.0144667. eCollection 2015. PLoS One. 2015. PMID: 26657401 Free PMC article. - Protein kinase C pharmacology: refining the toolbox.
Wu-Zhang AX, Newton AC. Wu-Zhang AX, et al. Biochem J. 2013 Jun 1;452(2):195-209. doi: 10.1042/BJ20130220. Biochem J. 2013. PMID: 23662807 Free PMC article. Review. - Zinc Protoporphyrin Upregulates Heme Oxygenase-1 in PC-3 Cells via the Stress Response Pathway.
Kwok SC. Kwok SC. Int J Cell Biol. 2013;2013:162094. doi: 10.1155/2013/162094. Epub 2013 Feb 17. Int J Cell Biol. 2013. PMID: 23476651 Free PMC article. - BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo.
Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, Grauert M, Hoffmann M, Schnapp G, Steegmaier M, Cohen P, Alessi DR. Sapkota GP, et al. Biochem J. 2007 Jan 1;401(1):29-38. doi: 10.1042/BJ20061088. Biochem J. 2007. PMID: 17040210 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials